Skip to Main Content
YSM Home

INFORMATION FOR

DownloadHi-Res Photo

Stuart Seropian, MD

Professor of Internal Medicine (Hematology); Acting Director, Stem Cell Transplantation; Chairman, Car-T Cell Joint Steering Committee; Director, Unrelated Donor Transplant Program, Stem Cell Transplantation; Co-Director, Immune Effector Cell Therapy; Co-Director, Adult CAR T-Cell Therapy Program

Contact Information

Stuart Seropian, MD

Mailing Address

  • Yale Cancer Center

    PO Box 208028, 333 Cedar Street, TMP 3

    New Haven, CT 06520-8028

    United States

Related Links

Yale Medicine

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Research Summary

Research endeavors include studies to improve outcomes of stem cell transplantation including novel agents to more effectively treat leukemia and new agents to reduce the risk of complications related to therapy.

Coauthors

Research Interests

Hematologic Diseases; Hematopoietic Stem Cells; Hodgkin Disease; Leukemia; Lymphocytes; Lymphoma; Lymphoma, Non-Hodgkin; Plasma Cells; Bone Marrow Transplantation; Clinical Trials, Phase III as Topic

Public Health Interests

Cancer; Clinical Trials

Selected Publications

Clinical Trials

ConditionsStudy Title
LungAn Open-Label, Multi-Centre Phase I/IIa Study Evaluating the Safety and Clinical Activity of Neoantigen Reactive T Cells in Patients With Advanced Non-Small Cell Lung Cancer
Non-Hodgkin's LymphomaA Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
Non-Hodgkin's LymphomaA Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL)
Multiple MyelomaNovel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
Multiple MyelomaEffective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
Non-Hodgkin's LymphomaA Phase 1, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Relapsed or Refractory T or B Cell Malignancies
Non-Hodgkin's LymphomaA Multi-center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects With Relapsed and/or Refractory Diffuse Large B Cell Lymphoma
Multiple MyelomaA Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
Multiple MyelomaDaratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Hodgkin's Lymphoma; Lymphoid Leukemia; Non-Hodgkin's LymphomaManaged Access Program (MAP) to Provide Access to CTL019, for ALL or DLBCL Patients With Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release
Anus; Breast - Female; Breast - Male; Colon; Corpus Uteri; Esophagus; Hodgkin's Lymphoma; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, skin; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid; Phase I; Unknown Sites; Breast; Cervix; Urinary BladderPhase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer
Non-Hodgkin's LymphomaA Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Non-Hodgkin's LymphomaAn Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Hodgkin's Lymphoma; Lymphoid LeukemiaA Phase Ia/Ib Study of a Novel BTK Inhibitor, DTRMWXHS-12, and Combination Products, DTRM-505 and DTRM-555, in Patients With Chronic Lymphocytic Leukemia or Other B-cell Lymphomas
Multiple MyelomaA Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma
Edit Profile